CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...
CanSino Biologics
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...
Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development
The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to...
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...
CanSino Biologics to Expand Southeast Asian Presence with Solution Group Berhad Stake
China-based CanSino Biologics (SHA: 688185, HKG: 6185) is poised to acquire an undisclosed amount of...
CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...
CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children
CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...
CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework...
CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...
CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140...
CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...
CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine
CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine
China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...
CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...
CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...
CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies
China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...
CanSino Biologics’ Inhalable COVID-19 Vaccine Authorized in Morocco
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...